Streetbeat News

Products Services

WKSP

Worksport Ltd. announces the assembly of the COR battery system in Canada using both domestic and foreign parts. The company has partnered with a Canadian manufacturer specializing in electronic boards to assemble the COR unit, including its inverter and hub. This move aligns with Worksport's commitment to quality and sustainability in the renewable energy sector. The announcement follows the news of the upcoming Alpha Release of the COR battery system for real-world testing and precedes the market launch. Worksport is also increasing production of tonneau covers due to a $16 million sales agreement and will provide updates on the SOLIS solar cover after the COR battery system's test phase.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:05 pm

TRU

TransUnion (TRU) and FreeWheel have announced an expanded partnership aimed at improving audience match rates within the TV advertising ecosystem. This collaboration will leverage TransUnion's data and insights to enhance FreeWheel's capabilities in targeting and measuring TV audiences more effectively.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:04 pm

GOOS

Canada Goose has acquired the operating assets of Paola Confectii Manufacturing, a Romanian knitwear supplier, marking its first European manufacturing facility. This move aligns with the company's Strategic Growth Plan to expand categories and increase year-round relevance. The acquisition is expected to enhance product margins, supply control, and in-house expertise. Knitwear is a key segment in Canada Goose's growing Apparel category, which surpassed $70 million in annual sales in fiscal 2023. The company will continue to produce core down-filled products in Canada, while expanding apparel production in Europe.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:04 pm

EFTR

eFFECTOR Therapeutics has been granted FDA Fast Track Designation for Zotatifin in combination with Fulvestrant and Abemaciclib for the treatment of ER+/HER2- advanced metastatic breast cancer. This designation could expedite the development and review process for Zotatifin, potentially bringing it to market more quickly if it proves to be safe and effective.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:03 pm

YTRA

Yatra Online has entered into a partnership with Aramco Asia to cater to the travel needs in the region. This collaboration aims to address the increasing demand for travel services in Asia by leveraging Yatra's expertise in travel management and Aramco's presence in the region.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:03 pm

ACRV

Acrivon Therapeutics has announced that the FDA has granted a device designation for its ACR-368 OncoSignature Assay, which is used in a Phase 2 trial to predict patient response to the CHK1/2 inhibitor ACR-368 for ovarian cancer. The assay is part of Acrivon's AP3 platform, which aids in drug design and understanding resistance mechanisms.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:03 pm

ACN

SAP

Accenture (ACN) is partnering with SAP SE to develop a supply chain nerve center aimed at reducing risk, enhancing visibility, and supporting sustainability goals. The collaboration will focus on co-developing new capabilities for SAP's Integrated Business Planning for Supply Chain (SAP IBP) solution, enabling organizations to respond more effectively to changes in supply, demand, and inventory.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:01 pm

CMND

Clearmind Medicine has reported positive outcomes from a pre-clinical trial, suggesting potential effects in improving metabolic parameters such as fat oxidation, weight loss, and reduced appetite.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:00 pm

CMND

SPRC

Clearmind Medicine Inc (NASDAQ:CMND) and SciSparc Ltd (NASDAQ:SPRC) have reported positive preclinical trial results for a combination therapy treating obesity and metabolic disorders. The therapy combines Clearmind's psychedelic MEAI and SciSparc's anti-inflammatory PEA. The trial found optimal dosages that increased metabolic processes and fat burn while reducing appetite and meal sizes without affecting animal viability. Clearmind also announced a 1-for-30 reverse share split effective today.

Portfolio Pulse from Vandana Singh

November 28, 2023 | 1:00 pm

CMND

Clearmind Medicine has announced positive pre-clinical results for its proprietary psychedelic-based treatment aimed at weight loss and metabolic disorders. The company's findings could pave the way for new treatments in the obesity and diabetes markets, which are areas of significant unmet medical need.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:00 pm